Intravitreal Aflibercept Outcomes in Patients with Persistent Macular Exudate Previously Treated with Bevacizumab and/or Ranibizumab for Neovascular Age-Related Macular Degeneration

Intravitreal Aflibercept Outcomes in Patients with Persistent Macular Exudate Previously Treated with Bevacizumab and/or Ranibizumab for Neovascular Age-Related Macular Degeneration

Saved in:

Bibliographic Details
Main Authors:	David R. Griffin, Preston P. Richmond, John C. Olson
Format:	Article
Language:	English
Published:	Wiley 2014-01-01
Series:	Journal of Ophthalmology
Online Access:	http://dx.doi.org/10.1155/2014/497178
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Comparison of Intravitreal Aflibercept and Ranibizumab following Initial Treatment with Ranibizumab in Persistent Diabetic Macular Edema
by: Ali Demircan, et al.
Published: (2018-01-01)

12-month outcomes of ziv-aflibercept for neovascular age-related macular degeneration in eyes previously treated with aflibercept
by: Wajiha J Kheir, et al.
Published: (2025-01-01)

Short-Term Results of Switch from Conbercept to Bevacizumab or Ranibizumab in Eyes with Persistent Neovascular Age-Related Macular Degeneration
by: Zongyi Wang, et al.
Published: (2020-01-01)

Switching to Aflibercept in Diabetic Macular Edema Not Responding to Ranibizumab and/or Intravitreal Dexamethasone Implant
by: Antoine Herbaut, et al.
Published: (2017-01-01)

Comparison of Progression Rate of Retinal Pigment Epithelium Loss in Patients with Neovascular Age-Related Macular Degeneration Treated with Ranibizumab and Aflibercept
by: Juliana Wons, et al.
Published: (2017-01-01)

Comparison of OCT Angiography Parameters after Administration of Intravitreal Brolucizumab versus Ranibizumab in Exudative Age-related Macular Degeneration
by: Sanjitha Vilma Moses, et al.
Published: (2024-12-01)

Two-Year Outcome of Aflibercept in Patients with Pigment Epithelial Detachment due to Neovascular Age-Related Macular Degeneration (nAMD) Refractory to Ranibizumab
by: Thi Ha Chau Tran, et al.
Published: (2017-01-01)

Intravitreal Aflibercept as a Rescue Therapy for Retinal Neovascularization and Macular Edema due to Eales Disease
by: Ning-Yi Hsia, et al.
Published: (2021-01-01)

Macular Oedema in Idiopathic Macular Telangiectasia Type 1 Responsive to Aflibercept but Not Bevacizumab
by: O’Sam Shibeeb, et al.
Published: (2014-01-01)

Corrigendum to “Two-Year Outcome of Aflibercept in Patients with Pigment Epithelial Detachment due to Neovascular Age-Related Macular Degeneration (nAMD) Refractory to Ranibizumab”
by: Thi Ha Chau Tran, et al.
Published: (2018-01-01)

Outcomes of Abrupt Switch to Bevacizumab of Patients Undergoing Aflibercept Intravitreal Injections for Neovascular Age-Related Macular Degeneration in a Tertiary Center in Lombardy, Italy: A Real-Life Retrospective Analysis
by: Alessandro Randazzo, et al.
Published: (2021-01-01)

Intraocular inflammation after intravitreal injection of aflibercept 8 mg for treatment-refractory neovascular age-related macular degeneration: a case report
by: Nozomu Hashiya, et al.
Published: (2025-01-01)

Fixed Monthly versus Less Frequent Ranibizumab Dosing and Predictors of Visual Response in Exudative Age-Related Macular Degeneration
by: Seenu M. Hariprasad, et al.
Published: (2012-01-01)

The Diagnostic Capability of Swept Source OCT Angiography in Treatment-Naive Exudative Neovascular Age-Related Macular Degeneration
by: Daniel Ahmed, et al.
Published: (2021-01-01)

Response to Aflibercept Therapy in Three Types of Choroidal Neovascular Membrane in Neovascular Age-Related Macular Degeneration: Real-Life Evidence in the Czech Republic
by: Jan Nemcansky, et al.
Published: (2019-01-01)

Treatment of neovascular age-related macular degeneration: one year real-life results with intravitreal Brolucizumab
by: Settimio Rossi, et al.
Published: (2025-01-01)

Comparison of Intravitreal Aflibercept and Ranibizumab for Treatment of Myopic Choroidal Neovascularization: One-Year Results—A Retrospective, Comparative Study
by: Burak Erden, et al.
Published: (2019-01-01)

Three-Year Outcomes of Patients with Neovascular Age-Related Macular Degeneration Treated with Aflibercept under the National Health Insurance Program in Taiwan
by: Kang-Jung Lo, et al.
Published: (2020-01-01)

Relationship between Neovascular Density in Swept Source-Optical Coherence Tomography Angiography and Signs of Activity in Exudative Age-Related Macular Degeneration
by: Martin Stattin, et al.
Published: (2019-01-01)

Use of Imaging Modalities in Real Life: Impact on Visual Acuity Outcomes of Ranibizumab Treatment for Neovascular Age-Related Macular Degeneration in Germany
by: Joachim Wachtlin, et al.
Published: (2020-01-01)

Comparison of the Efficacy and Safety of Intravitreal Conbercept with Intravitreal Ranibizumab for Treatment of Diabetic Macular Edema: A Meta-Analysis
by: Xiaolei Sun, et al.
Published: (2020-01-01)

Vitrectomy for full-thickness macular hole developed during aflibercept treatment for wet age-related macular degeneration
by: Agnieszka Nowosielska
Published: (2024-12-01)

Macular Hole Progression after Intravitreal Bevacizumab for Hemicentral Retinal Vein Occlusion
by: Manish Nagpal, et al.
Published: (2011-01-01)

The first experience with brolucizumab for neovascular age-related macular degeneration
by: A.N. Kulikov, et al.
Published: (2022-05-01)

Switch to Aflibercept in Diabetic Macular Edema Patients Unresponsive to Previous Anti-VEGF Therapy
by: Filipe Mira, et al.
Published: (2017-01-01)

Pengaruh Bevacizumab Intravitreal terhadap Best Corrected Visual Acuity dan Central Macular Thickness pada Diabetic Macular Edema
by: Arini Ghaisa Atsari, et al.
Published: (2020-01-01)

Dry and neovascular “wet” age-related macular degeneration: Upcoming therapies
by: Audrey Yan, et al.
Published: (2025-01-01)

Early OCT Angiography Changes of Macular Neovascularization in Patients with Exudative AMD Treated with Brolucizumab in a Real-World Setting
by: Anne Rübsam, et al.
Published: (2022-01-01)

Postpartum Exudation of Idiopathic Quiescent Macular Neovascularization: A Narrative Review with a Related Case Report
by: Livio Vitiello, et al.
Published: (2024-12-01)

Extended Injection Intervals after Switching from Ranibizumab to Aflibercept in Macular Edema due to Central Retinal Vein Occlusion
by: Sylvia Nghiem-Buffet, et al.
Published: (2018-01-01)

A Meta-Analysis of Studies Evaluating Visual and Anatomical Outcomes in Patients with Treatment Resistant Neovascular Age-Related Macular Degeneration following Switching to Treatment with Aflibercept
by: Sophie Seguin-Greenstein, et al.
Published: (2016-01-01)

Comparison of optical coherence tomography vs. fluorescein angiography-based macular neovascularization classifications in age-related macular degeneration
by: Gábor G. Deák, et al.
Published: (2025-02-01)

Treatment for neovascular age-related macular degeneration: reasonable expectations of physicians and patients
by: A.B. Durasov
Published: (2021-09-01)

Antivascular Endothelial Growth Factor Agents for Neovascular Age-Related Macular Degeneration
by: Ilias Zampros, et al.
Published: (2012-01-01)

OCT Biomarkers in Neovascular Age-Related Macular Degeneration: A Narrative Review
by: Cristian Metrangolo, et al.
Published: (2021-01-01)

Efficacy Comparison of Intravitreal Anti-VEGF Therapy for Three Subtypes of Neovascular Age-Related Macular Degeneration: A Systematic Review and Meta-Analysis
by: Jianqing Li, et al.
Published: (2018-01-01)

Effectiveness of Intravitreal Ranibizumab in Nonvitrectomized and Vitrectomized Eyes with Diabetic Macular Edema: A Two-Year Retrospective Analysis
by: Ozgun Melike Gedar Totuk, et al.
Published: (2020-01-01)

Clinical Comparative Study of Intravitreal Injection of Triamcinolone Acetonide and Aflibercept in the Treatment of Diabetic Retinopathy Cystoid Macular Edema
by: Yanxia Zhu, et al.
Published: (2022-01-01)

Intra-operative Intravitreal Bevacizumab For Patients With Diabetic Macular Edema Undergoing Phacoemulsification with Foldable IOL Implantation
by: Haider Ali Chaudhry, et al.
Published: (2024-06-01)

Population Pharmacokinetics of Pegcetacoplan in Patients with Geographic Atrophy or Neovascular Age-related Macular Degeneration
by: Ryan L. Crass, PharmD, et al.
Published: (2025-03-01)